Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from XBI

2 Ways to Play the Big Pharma Patent Cliff

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

MarketBeat

3 Biotech ETFs for Diversified Innovation Exposure

Biotech ETFs provide the perfect balance of high-growth potential and diversified risk, offering investors access to healthcare breakthroughs. Given this backdrop, you might consider three biotech ETFs: iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT). Keep reading….

StockNews.com

3 Biotech ETFs for a Diversified Portfolio

The biotech industry is growing rapidly with solid advancements, and ETFs in this sector can offer great investment opportunities. Thus, it could be wise to invest in top biotech ETFs SPDR S&P Biotech ETF (XBI), VanEck Biotech ETF (BBH), and iShares Biotechnology ETF (IBB) for a diversified portfolio. Read on.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com

Don't Get Caught Holding Either of These ETFs

The Fed announced its fourth consecutive 75-basis-point interest rate increase yesterday and indicated that it could raise interest rates higher than expected. This is expected to keep the stock market under pressure in the upcoming months. Therefore, we think losing ETFs Ark Innovation (ARKK) and SPDR S&P Biotech (XBI) are…

StockNews.com

SVB Sees De-Risked Opportunity For This Newly Listed Norovirus Vaccine

SVB Leerink is initiating coverage of HilleVax Inc (NASDAQ:HLVX) shares with an Outperform rating and a $30 price target. The analyst believes the company’s potentially first-in-class infant norovirus vaccine HIL214 represents a uniquely de-risked opportunity. It estimates $625 million in risk-adjusted infant HIL214 sales in 2030E ($1 billion unadjusted). The outlook is supported by…

Benzinga

The Best Health Care ETFs to Buy

The best health care ETFs offer diversification across medical industries as well as exposure to a sector with lower volatility than the broader market.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

People

Jerome Powell

3,395 stories

Dipanjan BanchurSince

722 stories

Steven AdamsAfter

40 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

65 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.